{
    "paper_id": "ed36c74378d8664b3ba4c8c5e6e6f1ef41e6e33b",
    "metadata": {
        "title": "",
        "authors": [
            {
                "first": "Stelios",
                "middle": [
                    "F"
                ],
                "last": "Assimakopoulos",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Markos",
                "middle": [],
                "last": "Marangos",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Contents lists available at ScienceDirect"
        },
        {
            "text": "To the Editor, Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome associated with acute respiratory distress syndrome (ARDS), multiple organ failure and increased mortality. This syndrome is characterised by increased interleukin (IL)-2, IL-7, granulocyte colony stimulating factor, interferon-\u03b3 inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-\u03b1, and tumour necrosis factor (TNF)-\u03b1 [1] .",
            "cite_spans": [
                {
                    "start": 492,
                    "end": 495,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "ref_spans": [],
            "section": "Contents lists available at ScienceDirect"
        },
        {
            "text": "N-Acetylcysteine (NAC), a well-known mucolytic agent used in respiratory infections, is a thiol-containing free-radical scavenger and a precursor of glutathione [2] . Reactive oxygen species and oxidative stress activate important redox-sensitive transcription factors like NF-\u03baB and activator protein-1, which lead to the co-ordinate expression of proinflammatory genes of IL-6, IL-8, and TNF-\u03b1 [3] .",
            "cite_spans": [
                {
                    "start": 161,
                    "end": 164,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 396,
                    "end": 399,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "Contents lists available at ScienceDirect"
        },
        {
            "text": "The beneficial action of 1200 mg/d of oral NAC in respiratory diseases has been previously demonstrated in prevention of chronic obstructive pulmonary disease exacerbations [2] . Moreover, a recent study including patients with community-acquired pneumonia, showed that the addition of this dose of NAC to conventional treatment improves oxidative stress and inflammatory response [4] . The positive effects of NAC in viral lower respiratory tract infections have been associated with inhibition of IL-8, IL-6, and TNF-\u03b1 expression and release in alveolar type II cells infected with influenza virus A and B and respiratory syncytial virus [5] .",
            "cite_spans": [
                {
                    "start": 173,
                    "end": 176,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 381,
                    "end": 384,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 640,
                    "end": 643,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Contents lists available at ScienceDirect"
        },
        {
            "text": "The results of these studies offer reasonable basis for the addition of 1200 mg/d oral NAC on therapeutic schemes of patients with COVID-19, as a measure that could potentially prevent the development of the cytokine storm syndrome and ARDS. This hypothesis is worth clarifying in appropriately designed clinical studies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Contents lists available at ScienceDirect"
        },
        {
            "text": "No data from this manuscript were presented in a scientific meeting before.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Prior presentation"
        },
        {
            "text": "The article has no funding source.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Funding sources"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "COVID-19: consider cytokine storm syndromes and immunosuppression",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Mehta",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Mcauley",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Sanchez",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Tattersall",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Manson",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "1033--1037",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "N-acetylcysteine in COPD: why, how, and when?",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Sanguinetti",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Multidiscip Respir Med",
            "volume": "11",
            "issn": "8",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Inflammation, free radicals, and antioxidants",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Conner",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Grisham",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Nutrition",
            "volume": "12",
            "issn": "4",
            "pages": "274--281",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ju",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Medicine (Baltimore)",
            "volume": "97",
            "issn": "45",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mata",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Morcillo",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Gimeno",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cortijo",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Biochem Pharmacol",
            "volume": "82",
            "issn": "5",
            "pages": "548--55",
            "other_ids": {}
        }
    },
    "ref_entries": {},
    "back_matter": [
        {
            "text": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "acknowledgement"
        }
    ]
}